Laboratory data: beta-interferon interleukin-2 sequence boosts the innate and adaptive immune response in metastatic ER+ breast cancer patients in a state of clinical benefit (G0-G1 state) during hormone therapy. This evidence concerns the gene IL2 and breast carcinoma.